Holen Sie sich die Stockscreener-App
4.81
1.03%
-0.05
Schlusskurs vom Vortag:
$4.86
Offen:
$4.87
24-Stunden-Volumen:
1.11M
Relative Volume:
0.91
Marktkapitalisierung:
$1.83B
Einnahmen:
$775.09M
Nettoeinkommen (Verlust:
$-58.68M
KGV:
-36.27
EPS:
-0.1326
Netto-Cashflow:
$64.06M
1W Leistung:
-4.56%
1M Leistung:
+2.12%
6M Leistung:
-35.78%
1J Leistung:
-26.45%
1-Tages-Spanne:
$4.78
$4.9194
1-Wochen-Bereich:
$4.78
$5.25
52-Wochen-Spanne:
$4.09
$9.2599
Goodrx Holdings Inc Stock (GDRX) Company Profile
Firmenname
Goodrx Holdings Inc
Sektor
Branche
Telefon
(855) 268-2822
Adresse
2701 OLYMPIC BOULEVARD, SANTA MONICA
Vergleichen Sie GDRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
4.81 | 1.83B | 775.09M | -58.68M | 64.06M | -0.1326 |
|
VEEV
Veeva Systems Inc
|
225.79 | 36.66B | 2.66B | 665.91M | 1.08B | 4.05 |
|
DOCS
Doximity Inc
|
72.37 | 13.58B | 516.85M | 174.11M | 217.38M | 0.87 |
|
SOLV
Solventum Corp
|
73.02 | 12.61B | 8.26B | 66.00M | 1.17B | 0.3682 |
|
TEM
Tempus Ai Inc
|
68.09 | 10.72B | 640.44M | -743.28M | -206.93M | -11.29 |
|
HQY
Healthequity Inc
|
108.60 | 9.41B | 1.15B | 96.70M | -161.99M | 1.09 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-04 | Eingeleitet | Mizuho | Neutral |
| 2024-08-09 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-01-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-08-10 | Hochstufung | DA Davidson | Neutral → Buy |
| 2023-07-31 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | Eingeleitet | Citigroup | Buy |
| 2022-11-04 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-08-12 | Eingeleitet | DA Davidson | Neutral |
| 2022-06-10 | Herabstufung | Goldman | Buy → Neutral |
| 2022-06-06 | Fortgesetzt | BofA Securities | Buy |
| 2022-06-01 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-05-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-04-07 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-03-15 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | Bestätigt | Barclays | Overweight |
| 2022-03-01 | Bestätigt | BofA Securities | Neutral |
| 2022-03-01 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-01 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | Bestätigt | Evercore ISI | Outperform |
| 2022-03-01 | Bestätigt | Goldman | Buy |
| 2022-03-01 | Bestätigt | JP Morgan | Underweight |
| 2022-03-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-03-01 | Bestätigt | SVB Leerink | Outperform |
| 2022-01-07 | Eingeleitet | Goldman | Buy |
| 2021-12-21 | Eingeleitet | Stephens | Overweight |
| 2021-12-02 | Eingeleitet | Jefferies | Buy |
| 2021-08-31 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-08-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-04-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2021-01-25 | Eingeleitet | Guggenheim | Buy |
| 2020-11-19 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | Eingeleitet | Barclays | Equal Weight |
| 2020-10-19 | Eingeleitet | BofA Securities | Neutral |
| 2020-10-19 | Eingeleitet | Citigroup | Buy |
| 2020-10-19 | Eingeleitet | Cowen | Outperform |
| 2020-10-19 | Eingeleitet | Credit Suisse | Outperform |
| 2020-10-19 | Eingeleitet | Deutsche Bank | Hold |
| 2020-10-19 | Eingeleitet | Goldman | Neutral |
| 2020-10-19 | Eingeleitet | JP Morgan | Neutral |
| 2020-10-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-10-19 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2020-10-19 | Eingeleitet | UBS | Buy |
Alle ansehen
Goodrx Holdings Inc Aktie (GDRX) Neueste Nachrichten
GDRX DEADLINE ALERT: Bernstein Liebhard LLP Reminds GoodRx Holdings, Inc. Investors of Upcoming Deadline - ACCESS Newswire
GoodRx (GDRX) to Release Quarterly Earnings on Thursday - Defense World
Scott Wagner Appointed to GoodRx Board of Directors - The Healthcare Technology Report.
GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives $8.38 Consensus Target Price from Analysts - MarketBeat
Taking a look at what insiders are doing to gauge the GoodRx Holdings Inc (GDRX)’s direction - Knox Daily
IMC Chicago LLC Makes New Investment in GoodRx Holdings, Inc. (NASDAQ:GDRX) - Defense World
High Growth Tech Stocks in United States to Watch - Simply Wall St
Take off with GoodRx Holdings Inc (GDRX): Get ready for trading - SETE News
Analysts review GoodRx Holdings Inc’s rating - Knox Daily
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in GoodRx Holdings, Inc. with Losses to Contact the Firm - ACCESS Newswire
Stock Performance Spotlight: GoodRx Holdings Inc (GDRX) Ends the Day at 4.78, Down by -0.83 - The Dwinnex
How to interpret GoodRx Holdings Inc (GDRX)’s stock chart patterns - US Post News
GoodRx Holdings Inc (GDRX) Stock Price and Analyst Predictions - The News Heater
GoodRx Appoints Christopher A. McGinnis as Chief Financial Officer -February 05, 2025 at 04:05 pm EST - Marketscreener.com
GoodRx appoints CitizensRx's CEO as its new CFO - MSN
GoodRx Names Christopher McGinnis as CFO -February 05, 2025 at 05:13 pm EST - Marketscreener.com
Taking a Closer Look At GoodRx Holdings Inc (GDRX) Following Its Recent Trade - Knox Daily
GoodRx Holdings Appoints Christopher McGinnis as CFO - TipRanks
GoodRx Holdings, Inc. (GDRX) Appoints Christopher A. McGinnis as CFO - StreetInsider.com
GoodRx Strengthens Leadership: 30-Year Healthcare Finance Expert Takes CFO Helm - StockTitan
A new trading data show GoodRx Holdings Inc (GDRX) is showing positive returns. - SETE News
GoodRx (NASDAQ:GDRX) Shares Gap DownHere's Why - MarketBeat
JPMorgan Chase & Co. Has $169,000 Stake in GoodRx Holdings, Inc. (NASDAQ:GDRX) - Defense World
GoodRx Announces Date for Fourth Quarter and Full Year 2024 Earnings Release and Conference Call - Business Wire
Telemedicine GoodRx Has Potential To Excel, Close Valuation Gap By 2025, Analyst Says - MSN
GoodRx Q4 Earnings Call: Key Financial Revelations Coming February 27Mark Your Calendar - StockTitan
3 US Penny Stocks With Market Caps Over $300M To Watch - Simply Wall St
Is GoodRx Holdings (GDRX) the Best Affordable Stock Under $5 to Buy Now? - Insider Monkey
GoodRx Adds Pet Program - Los Angeles Business Journal
10 Best Affordable Stocks Under $5 to Buy Now - Insider Monkey
Millennium Management LLC Reduces Stake in GoodRx Holdings Inc - GuruFocus.com
GoodRx appoints Scott Wagner as new board director - MSN
Assenagon Asset Management S.A. Reduces Holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX) - MarketBeat
GoodRx, PBMs Sued Over Alleged Generics Price-Fix Scheme - Law360
Scott Wagner appointed Co-Chair of GoodRx Board - Investing.com
GoodRx Appoints Former Interim CEO Scott Wagner as Board Co-Chair, Bringing GoDaddy Success Story - StockTitan
Short Interest in GoodRx Holdings, Inc. (NASDAQ:GDRX) Declines By 5.8% - MarketBeat
GoodRx Holdings, Inc. Announces CFO Changes, Effective January 17, 2025 - Marketscreener.com
GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Barclays PLC Grows Position in GoodRx Holdings, Inc. (NASDAQ:GDRX) - Defense World
GoodRx Holdings, Inc. (NASDAQ:GDRX) Shares Acquired by Barclays PLC - MarketBeat
GoodRx Holdings announces CFO resignation; shares drop - MSN
GoodRx (NASDAQ:GDRX) Stock Price Down 8.4% Following Analyst Downgrade - Defense World
GoodRx stock falls on CFO resignation news By Investing.com - Investing.com Canada
More Zero-cost Virtual Healthcare Appointments Available to Those Affected by Wildfires in Southern California - GlobeNewswire Inc.
GoodRx Holdings CFO Resigns, Interim CFO Appointed - TipRanks
GoodRx announces CFO transition, appoints interim successor - Investing.com
Citigroup Lowers GoodRx (NASDAQ:GDRX) Price Target to $6.25 - Defense World
GoodRx (NASDAQ:GDRX) Price Target Lowered to $6.25 at Citigroup - MarketBeat
GoodRx (NASDAQ:GDRX) Stock Price Up 5.8%Should You Buy? - MarketBeat
Finanzdaten der Goodrx Holdings Inc-Aktie (GDRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
9.30%
2.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):